BioSpace News Archive

Elevar Therapeutics, Inc. announced the opening of its new corporate headquarters in Fort Lee, New Jersey.

ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, beginning at approximately 11:20 a.m. (Eastern Daylight Time) via webcast.

F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the Committee on Foreign Investment in the United States (“CFIUS”) has cleared the previously announced all-cash acquisition of the Company by invoX Pharma Limited (“invoX”).

Abbott (NYSE: ABT) has received U.S. Food and Drug Administration clearance for what will be the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States.

Synaptogenix, Inc. provided a corporate update and announced encouraging results of its analysis of secondary endpoints and post hoc analysis from its National Institute of Health - sponsored Phase 2 extended clinical trial evaluating the safety, tolerability, and long-term efficacy of Bryostatin-1 for the treatment of advanced Alzheimer’s disease.

Paragonix Technologies, Inc., a leading organ transplant company, announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners.

The Tisch MS Research Center of New York (MSRCNY) has published new research finding that microglia could be a potential therapeutic target for mesenchymal stem cell-derived neural progenitor cell (MSC-NP) therapy, an experimental approach to treating multiple sclerosis.

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes.

Cyclacel Pharmaceuticals, Inc. announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.

Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration Implant, announced it has entered into a distribution agreement with Veteran’s Health Medical Supply.